Nicox S.A. (NYSE Euronext Paris: COX) today announced it has established a new
Scientific Advisory Board (SAB) with international Key Opinions Leaders (KOLs)
in the ophthalmology field. The first SAB meeting will be held on November
14, 2013 in New Orleans, Louisiana, United States, with the objective of
evaluating the existing data on second generation nitric oxide (NO)-donors and
discussing their potential therapeutic use in certain ophthalmic disorders.

Nicox's SAB will be led by Dr. Richard L. Lindstrom, founder and attending
surgeon at Minnesota Eye Consultants and Adjunct Clinical Professor Emeritus at
the University of Minnesota Department of Ophthalmology. Dr. Lindstrom is an
internationally recognized leader in corneal, cataract, refractive and laser
surgery.

AAO 2013

Nicox will attend the 2013 Annual Meeting of the American Academy of
Ophthalmology (AAO), taking place from November 16 to 18, 2013 in New Orleans,
Louisiana, United States. Nicox can be found at booth number 4719. Nicox's US
and European operational teams will attend the meeting, as well as several
members from the Executive team.

About Dr. Richard L. Lindstrom

Dr Richard L. Lindstrom is Founder and attending surgeon at Minnesota Eye
Consultants, Adjunct Clinical Professor Emeritus at the University of Minnesota
Department of Ophthalmology. He serves as Associate Director at the Minnesota
Lions Eye Bank and as Board Member at the University of Minnesota Foundation. He
is also Visiting Professor at UC Irvine's Gavin Herbert Eye Institute and he
serves on the Board of Directors of several publicly traded and private
companies and on a number of Journal editorial boards.

Dr Lindstrom is a board-certified ophthalmologist and internationally recognized
leader in corneal, cataract, refractive and laser surgery. He has been at the
forefront of ophthalmology's evolutionary changes throughout his career, as a
recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed
physician and surgeon. He holds over 38 patents in ophthalmology and has
developed a number of solutions, intraocular lenses and instruments that are
used in clinical practices globally.

...................................


About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company
focused  on the ophthalmic  market. With a  heritage of innovative R&D, business
development  and commercial expertise, the Nicox  team is building a diversified
portfolio  of therapies  and diagnostic  tools that  can help  people to enhance
their  sight. The Company's commercial  portfolio and near-term pipeline already
include several innovative diagnostic tests intended for eye care professionals,
as  well  as  a  range  of  eye  care products. Nicox's key proprietary asset in
ophthalmology  is  latanoprostene  bunod,  a  novel  compound  based  on Nicox's
proprietary  nitric  oxide  (NO)-donating  R&D  platform,  currently in Phase 3
clinical  development  in  collaboration  with  Bausch  + Lomb for the potential
treatment  of  glaucoma  and  ocular  hypertension.  Further NO-donors are under
development, notably through partners.


Nicox is headquartered in France, with research capabilities in Italy, a growing
commercial infrastructure in North America and in the major European markets and
an  expanding international presence  through partners. Nicox  S.A. is listed on
Euronext  Paris (Compartment B: Mid Caps). For  more information on Nicox or its
products please visit www.nicox.com.
..................................

This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated in
the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are
presented in the 4th chapter of the « Document de référence, rapport financier
annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés
Financiers (AMF) on March 22, 2013 and available on Nicox's website
(www.nicox.com) and on the AMF's website (www.amf-france.org).

...................................


 Nicox Contact   Gavin Spencer | Executive Vice President Corporate Development

                 Tel +33 (0)4 97 24 53 00 | communications@nicox.com

 Media Relations



 Europe          FTI Consulting

                 Julia Phillips | D+44 (0)20 7269 7187 | M +44 (0) 7770 827 263

                 Julia.Phillips@fticonsulting.com

                 Stephanie Cuthbert | D +44 (0)20 3077 0458 | M +44 (0)
                 7843 080947

                 Stephanie.Cuthbert@fticonsulting.com

                 Mo Noonan | D +44 (0)20 7269 7116 | M +44 (0)7876 444 977

                 Mo.Noonan@fticonsulting.com

 United States   Pascale Communications

                 Amy Phillips | M +1 412 327 9499

                 Amy@pascalecommunications.com
                 

Nicox holds first ophthalmology Scientific Advisory Board : http://hugin.info/143509/R/1739749/584003.pdf

[HUG#1739749]
Cox Communications (NYSE:COX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Cox Communications Charts.
Cox Communications (NYSE:COX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Cox Communications Charts.